Valuation: Charles River Laboratories International, Inc.

Market Cap 1.44TCr 1.29TCr 1.2TCr 1.09TCr 2.05TCr 1,36800Cr 2.06TCr 14TCr 5.63TCr 71TCr 5.41TCr 5.29TCr 2,28300Cr P/E 2026 *
72.3x
P/E 2027 * 31.6x
Enterprise Value 1.65TCr 1.47TCr 1.37TCr 1.25TCr 2.34TCr 1,56600Cr 2.36TCr 16TCr 6.44TCr 81TCr 6.2TCr 6.06TCr 2,61400Cr EV / Sales 2026 *
4.21x
EV / Sales 2027 * 4.01x
Free-Float
95.58%
Yield 2026 *
-
Yield 2027 * -
07:22pm Magellan Stem Cells Collaborates with Charles River Laboratories International, Inc. to Advance Stem Cell and Regenerative Medicine Development CI
06:50pm Charles River Laboratories Working With Magellan Stem Cells to Test Osteoarthritis Therapy MT
12/10 Morgan Stanley Adjusts Price Target on Charles River Laboratories International to $340 From $300 MT
06/10 Charles River Laboratories International, Inc. and Autolomous Launch Apollo Orchestrate Within Charles River's Apollo Platform CI
30/09 UBS Upgrades Charles River Laboratories International to Buy From Neutral, Adjusts Price Target to $357 From $175 MT
29/09 PMGC Unit Working With Charles River Laboratories for Muscle Health Probiotic Testing MT
28/09 Jefferies Adjusts PT on Charles River Laboratories International to $340 From $305, Maintains Buy Rating MT
25/09 Charles River Laboratories's DAS Segment Faces Largest Margin Upside, RBC Says MT
25/09 Deutsche Bank Raises Price Target on Charles River Laboratories International to $320 From $300, Keeps Buy Rating MT
25/09 RBC Raises Price Target on Charles River Laboratories International to $322 From $282, Keeps Outperform Rating MT
25/09 Evercore ISI Adjusts PT on Charles River Laboratories International to $330 From $320, Maintains Outperform Rating MT
25/09 Mizuho Adjusts PT on Charles River Laboratories International to $295 From $264, Keeps Neutral Rating MT
25/09 Barclays Adjusts PT on Charles River Laboratories International to $330 From $300, Keeps Overweight Rating MT

Last Transcript: Charles River Laboratories International, Inc.

1 week-2.82%
Current month+2.28%
1 month+8.64%
3 months+29.45%
6 months+71.97%
Current year+51.39%
1 week 288.66
Extreme 288.66
332.69
1 month 267.37
Extreme 267.37
332.69
3 years 91.87
Extreme 91.87
332.69
5 years 91.87
Extreme 91.87
449.21
10 years 67.23
Extreme 67.23
460
Manager TitleAgeSince
Chief Executive Officer 56 05/05/2026
Director of Finance/CFO 58 06/04/2026
Chief Tech/Sci/R&D Officer 45 12/01/2026
Director TitleAgeSince
Chairman 75 01/01/2000
Director/Board Member 56 05/05/2026
Chairman 69 05/05/2026
Change 5-day change 1-year change 3-year change Capi.($)
-1.07%+3.99%+80.90%+59.91% 1.44TCr
-0.32%-5.97%+50.26%+76.20% 7.06TCr
-1.99%-11.55%+4.84%+49.58% 5.12TCr
-1.32%-1.46%+7.39%+31.23% 4.8TCr
-0.58%-2.03%+31.54%+31.92% 4.32TCr
-2.84%-9.26%+290.63%+678.68% 4.16TCr
-0.38%-3.48%+9.05%+98.08% 3.98TCr
-0.39%-1.59%+8.69%+42.99% 3.09TCr
-2.66%-7.49%+35.37%+3.22% 2.75TCr
-7.13%-8.84%-12.79%-18.26% 2.41TCr
Average -1.93%-3.92%+50.59%+105.35% 4.19TCr
Weighted average by Cap. -1.57%-4.29%+51.25%+114.37%

Financials

2026 *2027 *
Net sales 391.71Cr 349.92Cr 326.15Cr 295.7Cr 556.48Cr 37TCr 560.86Cr 3.91TCr 1.53TCr 19TCr 1.47TCr 1.44TCr 62TCr 401.82Cr 358.95Cr 334.57Cr 303.33Cr 570.84Cr 38TCr 575.33Cr 4.01TCr 1.57TCr 20TCr 1.51TCr 1.48TCr 64TCr
Net income 19Cr 17Cr 16Cr 14Cr 27Cr 1.81TCr 27Cr 190.55Cr 75Cr 943.07Cr 72Cr 70Cr 3.03TCr 44Cr 39Cr 36Cr 33Cr 62Cr 4.15TCr 63Cr 435.98Cr 170.67Cr 2.16TCr 164.16Cr 160.55Cr 6.92TCr
Net Debt 209.15Cr 186.83Cr 174.14Cr 157.88Cr 297.12Cr 20TCr 299.46Cr 2.09TCr 816.66Cr 10TCr 785.48Cr 768.24Cr 33TCr 170.76Cr 152.54Cr 142.18Cr 128.91Cr 242.6Cr 16TCr 244.5Cr 1.7TCr 666.79Cr 8.43TCr 641.32Cr 627.25Cr 27TCr
Projected Income Statement - Annual - Charles River Laboratories International, Inc.
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
-
Date Price Change
14/26/14 $299.04 -1.07%
12/26/12 $302.27 +0.10%
09/26/09 $301.96 +1.28%
08/26/08 $298.13 -0.72%
07/26/07 $300.29 -1.63%
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Charles River Laboratories International, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
301.86USD
Average target price
313.20USD
Spread / Average Target
+3.76%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Charles River Laboratories International, Inc.